Biologika als Erstlinientherapie bei chronisch entzündlichen Darmerkrankungen – contra

Schlüsselwörter

chronisch entzündliche Darmerkrankungen - Morbus Crohn - Biologika - Erstlinientherapie

Keywords

chronic inflammatory bowel disease - Crohn's disease - biologicals - first-line therapy

Literatur

• 1 Colombel J F. et al . Infliximab, azathioprine, or combination therapy for Crohn’s disease.  N Engl J Med. 2010;  362 1383-1395
• 2 Hanauer S B. et al . Maintenance infliximab for Crohn’s disease.  Lancet. 2002;  359 1541-1549
• 3 Colombel J F. et al . Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease.  Gastroenterology. 2007;  132 52-65
• 4 D’Haens G. et al . Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease.  Lancet. 2008;  371 660-667
• 5 Cullen G, Keegan D, Mulcahy H E, O’Donoghue D P. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn’s disease.  Clin Gastroenterol Hepatol. 2009;  7 323-328
• 6 Cottone M. et al . Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.  Clin Gastroenterol Hepatol. 2011;  9 30-35